PIEZO1 and triple-negative breast carcinoma: Consistent with our findings, Poole et al. [19] demonstrated that high PIEZO1 expression is associated with poorer clinical outcomes in hormone receptor-negative breast cancer patients, particularly those with triple-negative breast cancer.